102 related articles for article (PubMed ID: 10226560)
1. Combined antitumour activity of mitomycin C, 5-fluorouracil and interleukin-2 against human colon cancer cells.
Ishihara M; Kubota T; Watanabe M; Kawano Y; Narai S; Yasui N; Otani Y; Teramoto T; Kitajima M
Anticancer Res; 1999; 19(1A):313-6. PubMed ID: 10226560
[TBL] [Abstract][Full Text] [Related]
2. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
4. Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
Higashihara J; Berens ME; Collins LA; Homesley HD; Welander CE
Gynecol Oncol; 1993 Feb; 48(2):171-9. PubMed ID: 8428687
[TBL] [Abstract][Full Text] [Related]
5. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of recombinant interferon-alpha and 5-fluorouracil against colon cancer cells or against peripheral blood mononuclear cells.
De Filippi R; Prete SP; Giuliani A; Silvi E; Yamaue H; Nieroda CA; Greiner JW; De Vecchis L; Bonmassar E
Anticancer Res; 1994; 14(5A):1767-73. PubMed ID: 7847809
[TBL] [Abstract][Full Text] [Related]
7. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
[TBL] [Abstract][Full Text] [Related]
8. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
9. [Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3].
Chen R; Pan L; Zhou S
Zhonghua Fu Chan Ke Za Zhi; 1999 Mar; 34(3):172-4. PubMed ID: 11263191
[TBL] [Abstract][Full Text] [Related]
10. [Synergistic effects of tumor necrosis factor interferon-gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro].
Li J; Hui N; Zhu L
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):429-31. PubMed ID: 8697994
[TBL] [Abstract][Full Text] [Related]
11. Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients.
Kamamura Y; Takahashi K; Komaki K; Monden Y
J Med Invest; 1998 Aug; 45(1-4):71-5. PubMed ID: 9864966
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy prevents human colon cancer metastasis after orthotopic onplantation of histologically-intact tumor tissue in nude mice.
Furukawa T; Kubota T; Watanabe M; Kuo TH; Kase S; Saikawa Y; Tanino H; Teramoto T; Ishibiki K; Kitajima M
Anticancer Res; 1993; 13(2):287-91. PubMed ID: 8517641
[TBL] [Abstract][Full Text] [Related]
13. [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor].
Miya K; Saji S; Furuta T; Azuma S; Umemoto T; Takao H; Katou M; Kanno A; Kaneda N; Yamawaki Y
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1453-6. PubMed ID: 1530292
[TBL] [Abstract][Full Text] [Related]
14. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
15. [The effect of interleukin-2, interleukin-4 and tumor necrosis factor on LAK cells activity].
Zeng Z; Si CW; Yu M
Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):235-7, 256. PubMed ID: 7922766
[TBL] [Abstract][Full Text] [Related]
16. Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy.
Moriyama M; Hoshida Y; Kato N; Otsuka M; Yoshida H; Kawabe T; Omata M
Int J Oncol; 2004 Nov; 25(5):1279-87. PubMed ID: 15492816
[TBL] [Abstract][Full Text] [Related]
17. Interferon gamma increases the antitumor activity of mitomycin C against human colon cancer cells in vitro and in vivo.
Ishihara M; Kubota T; Watanabe M; Kawano Y; Narai S; Yasui N; Otani Y; Teramoto T; Kitajima M
Oncol Rep; 1999; 6(3):621-5. PubMed ID: 10203603
[TBL] [Abstract][Full Text] [Related]
18. [Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer].
Sugiyama Y; Kato M; Takao H; Kida H; Kunieda K; Umemoto T; Miya K; Azuma S; Furuta T; Saji S
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1461-4. PubMed ID: 8373205
[TBL] [Abstract][Full Text] [Related]
19. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
Ishii T; Marumo K
Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
[TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative and cytokinetic effects of tumor necrosis factor-alpha, interferon-alpha and 5-fluorouracil on a human tumor xenograft.
Tanaka N; Kojima K; Muro M; Naomoto Y; Moreira LF; Orita K
Anticancer Res; 1995; 15(5B):1949-52. PubMed ID: 8572582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
